Literature DB >> 6178916

Inosiplex in recurrent herpes simplex infections.

M Galli, A Lazzarin, M Moroni, C Zanussi.   

Abstract

Mesh：

Substances：

Year:  1982        PMID： 6178916     DOI： 10.1016/s0140-6736(82)90300-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Randomised, double blind, placebo controlled trial of inosine pranobex in rheumatoid arthritis.

Authors:  M Brzeski; R Madhok; J A Hunter; H A Capell
Journal:  Ann Rheum Dis       Date:  1990-05       Impact factor: 19.103

2.  The experimental and clinical use of immune-modulating drugs in the prophylaxis and treatment of infections.

Authors:  J Drews
Journal:  Infection       Date:  1985       Impact factor: 3.553

3.  Suppression of frequently recurring genital herpes: acyclovir v inosine pranobex.

Authors:  A Mindel; O Carney; C Sonnex; M Freris; G Patou; P Williams
Journal:  Genitourin Med       Date:  1989-04

4.  The experimental and clinical use of immune-modulating drugs in the prophylaxis and treatment of infections.

Authors:  J Drews
Journal:  Infection       Date:  1984 Mar-Apr       Impact factor: 3.553

Review 5.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

Review 6.  Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.

Authors:  Jiri Sliva; Chrysoula N Pantzartzi; Martin Votava
Journal:  Adv Ther       Date:  2019-06-05       Impact factor: 3.845

Review 7.  Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course.

Authors:  Jiří Beran; Marián Špajdel; Jiří Slíva
Journal:  Viruses       Date:  2021-11-09       Impact factor: 5.048
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.